225 results about "Post transplant" patented technology

The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation, for instance by targeting the protein to a suitable secretory granule. Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation).

15-C isomers of rapamycin and of 42-C Epi rapamycin, and pharmaceutically acceptable salts or prodrugs thereof are disclosed. These compounds are potential immunomodulatory and anti-inflammatory agents, and may be useful in the treatment of restenosis and immune and autoimmune diseases. Also disclosed are cancer-, fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions comprising the invented isomers, and methods of inhibiting cancer, fungal growth, restenosois, post-transplant tissue rejection, and immune and autoimmune disease in a mammal. One particular preferred application of these novel rapamycin derivatives are in implantable medicated devices wherein the prolonged presence of these compound locally are essential to the success of drug containing combination devices.

An object of the present invention is to provide a cell construct for cell transplantation capable of having a thickness suitable for cell transplantation, preventing the necrosis of transplanted cells, and forming blood vessels in the transplantation site after transplantation. The present invention provides a cell construct for cell transplantation which comprises polymer blocks having biocompatibility and cells of at least one type, wherein the plural polymer blocks are arranged in spaces between the plural cells.

An exsanguinous metabolic support system for maintaining an organ or tissue at a near normal metabolic rate is disclosed. The system employs a warm perfusion solution capable of supporting the metabolism of the organ or tissue thereby preserving its functional integrity. The system also monitors parameters of the circulating perfusion solution, such as pH, temperature, osmolarity, flow rate, vascular pressure and partial pressure of respiratory gases, and regulates them to insure that the organ is maintained under near-physiologic conditions. Use of the system for long-term maintenance of organs for transplantation, for resuscitation and repair of organs having sustained warm ischemic damage, as a pharmaceutical delivery system and prognosticator of posttransplantation organ function is also disclosed.

Epimers and isomers of tetrazole-containing rapamycin analogs are immunomodulatory agents and are useful in the treatment of restenosis and immune and autoimmune diseases. Also disclosed are cancer-, fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosis, post-transplant tissue rejection, and immune and autoimmune disease in a mammal. It is preferred to use a combination of native rapamycin and its tetrazole containing isomers and epimers. One particular preferred application of such a combination of rapamycin and its tetrazole containing isomers and epimers is in medicated devices and local vascular delivery wherein the stability and lipid solubility and subsequently diffusion through tissue and cell membranes of the tetrazole isomers and epimers are essential to the success of the combined rapamycin formulation.

A rapamycin analog with an antioxidant moiety or a pharmaceutically acceptable salt or prodrug thereof, is an immunomodulatory agent and is useful in the treatment of restenosis and immune and autoimmune diseases. Also disclosed Are cancer-, fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosois, post-transplant tissue rejection, and immune and autoimmune disease in a mammal. One particular preferred application of such antioxidant moiety containing rapamycin analog is in medicated devices wherein the stability and resistance to oxidative processes are essential to the success of rapamycin containing combination devices.

The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.

The invention relates to a decellularization cornea preparation method, which adopts steps of corneal epithelium layer removing, ultraviolet cross-linking, viral inactivation, decellularization treatment, gradient dehydration, radiation protection and sterilization. According to the present invention, the prepared decellularization cornea has characteristics of complete antigen removing, no excitation of host acquired immunity reaction, good biocompatibility, low damage on nature corneal stroma, maintaining of structure characteristics of the nature corneal, and maintaining of effective components of the nature corneal so as to provide physical and chemical properties similar to the nature corneal; and after the prepared decellularization cornea is transplanted, animal experiment results show that characteristics of transparent transplanted cornea, no scar formation, no melting generation and no neovascularization are provided, the transplanted cornea and the recipient bed are completely integrated after transplanting a month, the transplanted cornea is subjected to complete epithelization after three months, corneal stroma cells migrate toward the decellularization cornea graft so as to prove that the tissue just takes place slow reconstruction, and the transplanted cornea after 6 months does not show significant difference in histology and appearance detection compared with the nature cornea.

An exsanguinous metabolic support system for maintaining an organ or tissue at a near normal metabolic rate is disclosed. The system employs a warm perfusion solution capable of supporting the metabolism of the organ or tissue thereby preserving its functional integrity. The system also monitors parameters of the circulating perfusion solution, such as pH, temperature, osmolarity, flow rate, vascular pressure and partial pressure of respiratory gases, and regulates them to insure that the organ is maintained under near-physiologic conditions. Use of the system for long-term maintenance of organs for transplantation, for resuscitation and repair of organs having sustained warm ischemic damage, as a pharmaceutical delivery system and prognosticator of posttransplantation organ function is also disclosed.

The invention discloses an adipose transplantation material containing highly concentrated adipose-derived stem cells and an extracellular matrix (ECM), and a pure physical preparation method and an application thereof; with application of a fluid vortex principle, most of mature adipocytes in an adipose tissue are broken; at the same time, with application of a flocculation sedimentation technology, oil droplets generated from breaking the adipocytes are gathered and removed. A series of mechanical processing processes are adopted, the pure physical means is adopted, and no any exogenous substances are added. The multiple physical methods are used for removing the mature adipocytes and grease affecting the tissue retention rate after transplantation. In a prepared SVF-gel, the adipose-derived stem cells and endothelial progenitor cells are highly concentrated; the concentrated stromal vascular fraction cells (SVFs) still adhere on the ECM, the number of stem cells fix-planted in local after transplantation is far greater than the ordinary adipose transplantation number; as a stem cell therapy method, the adipose transplantation material has better long-term curative effect.

The present invention relates to methods for culturing human retinal progenitor cells under low oxygen conditions to allow the cells to retain the ability to differentiate into photoreceptors following transplantation. The described methods provide cells that can treat a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration.

A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and / or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.

The present invention relates to a composition for preserving cells, tissues and organs, comprising as an active ingredient indole and indazole compounds of formula (1), or a pharmaceutically acceptable salt or isomer thereof, which are effective for preventing injury of organs, isolated cell systems or tissues caused by cold storage, transplant operation or post-transplantation reperfusion; a preservation method; and a preparation method of the composition.

The disclosure relates to methods to prevent, treat, or slow the progression viral-associated lymphoproliferative disorders, EBV-associated lymphoproliferative disorders, and post-transplant lymphoproliferative disorders. In the methods, a TGF-β antagonist, e.g., an anti-TGF-β antibody is administered to a subject. Methods for treating viral-associated lymphoproliferative disorders and for enhancing T-cell responsiveness to a viral-associated lymphoproliferative disorder by administering a TGF-β antagonist are also described.

The invention relates to a method for inducing a human pluripotent stem cell to differentiate into an RPE cell. According to the method, an inhibitor is used for inducing the human pluripotent stem cell to differentiate into a neural precursor; after Shh, IGF1 and EGF growth factors are utilized to activate ERK 1 / 2, JNK, Sonic hedgehog signal routes, the cell is presented as the shape of neuroepithelium, Activen A and Chir99021 are added to activate TGFbeta and Wnt signal routes respectively to induce a neuro-epithelial cell into a retinal progenitor cell; adherent culture is conducted on theretinal progenitor cell to obtain an RPE cell at an underdeveloped state. The invention further studies the field of applying the underdeveloped RPE cell to treating retinal degenerative diseases. Compared with the prior art, the method firstly makes three stages of differentiating the human pluripotent stem cell to the underdeveloped RPE cell and related small molecular substances and growth factors used therein clear. Compared with a matured RPE, the underdeveloped RPE obtained through differentiation can treat the retinal degenerative diseases more effectively after being transplanted.

The invention relates to a method for winter accelerating germination and seedling culture of Radix millettiae Speciosae seeds. The method comprises the steps of seedbed and substrate preparation, seed dormancy breaking, seed accelerating germination, seeding, seedbed management, and transplant and post-transplant management. The provided method for the winter accelerating germination and seedling culture of the Radix millettiae Speciosae seeds is capable of guaranteeing the seed maturity through the drying and after-ripening, guaranteeing the seed plumpness through the water separation and purification, preventing the seed mildew through the surface sterilization, guaranteeing the abundant water absorption of the seed through the hydro-priming, effectively promoting the germination of the Radix millettiae Speciosae seeds through the culture under 5-10 days of the suitable sprouting conditions, guaranteeing the seedling formation through the small shed containerized seedling, and greatly improving the germination rate of the Radix millettiae Speciosae seeds in winter.

An isolated population of cells comprising non-GVHD inducing anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype is provided. The cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation. Methods of generating same, use of same and methods of treatment are also provided.

An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is disclosed. Methods of generating same and using same are also disclosed.

The invention discloses a preparation method of an autologous mesenchymal stem cell-loaded human amniotic membrane cornea paster, wherein autologous sourced mesenchymal stem cells are planted onto an amniotic membrane to be taken as bearing carriers to treat the corneal injury. The method comprises the following steps of: inoculating monocyte separated from bone marrow into an alpha-MEM culture medium, amplifying to a third generation to inoculate 2.5*10<5> cells onto the 1.2cm*1.2cm amniotic membrane, and tightly arranging the cells after 48 hours, wherein the cover area of the mesenchymal stem cell under an inverted microscope is greater than 80%, and the immunofluorescent staining shows that the positive rate of cells CD44 and CD90 is greater than 90%. The human amniotic membrane-loaded mesenchymal stem cell paster is free from dissolving and falling after being transplanted within one week, and new vessels can not be generated within eight months. The method is free from immunological rejection, an enough cell source can be provided, and the method can be used for the clinic treatment of the corneal injury.

An acellular dermal graft is provided. The acellular dermal graft may be useful in minimizing side effects caused after transplantation since an environment favorable for formation of new blood vessels and proliferation of autologous tissues is provided by forming a multi-penetration structure in an acellular dermal tissue, removing a basement membrane layer and / or subjecting corners to slope cutting, and transplantation is stably performed within a short transplantation time due to improved extensibility and flexibility of tissues. The acellular dermal graft may be useful in reducing a time required to recover tissues after transplantation since the transplantation is stably performed due to improved grafting reaction with a host tissue by enhancing uptake of fibroblasts and promoting angiogenic activities. Also, the acellular dermal graft may be useful in maintaining smooth external appearance since hypodermic implantation is easily performed upon transplantation, and the skin at a graft site does not protrude after transplantation.

The invention relates to a method to prepare and preserve homogeneous bioactive bone tissue, its steps: 1, obtaining: on the aseptic condition, obtaining homogeneous bone tissue; 2, finishing: eliminating soft tissue and periosteum, eliminating bone marrow tissue, and reserving partial joint bursa, ligament and adhesive point of muscle; 3, defatting: dipping in chloroformic methanol, washing with physiological saline and then packaging; 4, gradient temperature reducing: placing the preprocessed bone tissue in program temperature reducer to make gradient temperature reduction up to -40 deg.C--60 deg.C for 20-80 min.; 5, preserving: putting the bone tissue in the -60 deg.C - 80 deg. C refrigerator. It can keep the integrality of bone ultramicro structure, bone inducing activity, bioforce intensity and maintain a certain quantity of survival soft bone cells.

The invention discloses a rapid breeding method suitable for Camellia camellia in mountainous areas, comprising: S1, treatment of Camellia camellia mother tree: selecting side branches on the mother camellia camellia tree and peeling them circularly; S2, preparing large cuttage stems: cutting and girdling treatment After the side branch, the top is sealed with wax, and the girdling mouth on the side branch is soaked in indole acetic acid solution to obtain a large cuttage; S3, making the rooting matrix: S4, rooting treatment in the cutting box: the rooting matrix in S3 and the cuttings obtained in S2 Put the large poles into the cutting box for root-promoting treatment to obtain cutting seedlings; S5, transplanting and post-processing: after the root system of the cutting seedlings grows to 3cm, take the cutting seedlings out of the cutting box and move them to the hillside for planting. The present invention adopts large poles for cuttings, uses a cutting box to accelerate root growth, and develops the root system, so as to improve the rooting rate and transplanting survival rate of camellia camellia, and realize the efficient breeding of camellia camellia.

The invention provides a method for detecting post-transplantation GVHD related cytokines by using flow cytometry and a detection kit. The method and the detection kit have important clinical significance in the aspects of early evaluation and diagnosis of post-transplantation GVHD. According to the detection method and the kit, indexes of one or more different combinations of cell factors IL-6, IL-8, ST2, Reg3[alpha], Elafin, TNFR1, soluble IL-2R and HGF related to GVHD diagnosis and prognosis can be rapidly and homogeneously detected at the same time; single-sample multiple detection is achieved, time and resources are saved, and the result is automatically analyzed by software so as to be more objective and accurate. The method is simple, convenient, safe in detection and small in sample use quantity. By the application of the method, the risk of the GVHD of the transplanted patient can be evaluated timely, quickly and stably for a long time, the accuracy and timeliness of treatmentof the patient are improved, and the life of the patient is saved.

The invention discloses an adult sertoli cell-pancreas islet compound and a preparation method for the same, which solve the problem of influence on pancreas islet transplantation effect due to the transplant dysfunction because the pancreas islet separated and purified presently generates hypoxic-ischemic and immunological rejection reactions after being transplanted and then loses the function. The preparation method comprises the following steps of: 1, separating and purifying adult pancreas islet by adopting a semi-automatic filling and continuous density gradient methods; 2, separating and purifying adult sertoli cells by adopting a two-step digestion method; and 3, constructing the pancreas islet-sertoli cell compound by adopting a specific co-culture method. The adult sertoli cell-pancreas islet compound and the preparation method for the same disclosed by the invention have the advantage that pancreas islet cells and sertoli cells are coupled into a compound, the compound is used as a transplant, and the sertoli cells are attached to the surface of the pancreas islet, so as to improve the nutritional status of the pancreas islet, inhibit rejection reaction, and increase the survival rate of the pancreas islet; the operation is simple and convenient; and the success rate is high.

A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and / or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.

The present invention discloses a low immunogenicity non-human animal skin, a preparation method and applications thereof, wherein the low immunogenicity non-human animal skin is a non-human animal skin with clearing of heterologous antigen alpha-galactose (alpha-Gal) on the cell surface through a recombinant alpha-galactosidase enzymolysis treatment. The non-human animal skin has a characteristic of low immunogenicity, wherein the mainly reason is clearing of heterologous antigen alpha-Gal so as to prolong an occurrence time of an immunological rejection reaction after transplantation. In addition, the non-human animal skin can be provided for covering burning wound surfaces of burn patients, reducing immunological rejections during heterologous transplantation processes, and prolonging survival times of animal skins on burning wound surfaces so as to achieve purposes of wound surface healing promoting and scarring reducing.

A semi-synthetic rapamycin analog with a triazole moiety or a pharmaceutically acceptable salt or prodrug thereof, is a broad-spectrum cytostatic agent and a mTOR inhibitor, and is useful in the treatment of various cancers, or tumors in organs such as kidney, liver, breast, head and neck, lung, prostate, and restenosis in coronary arteries, peripheral arteries, and arteries in the brain, immune and autoimmune diseases. Also disclosed are fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosois, post-transplant tissue rejection, and immune and autoimmune disease in a mammal. One particular preferred application of such triazole-moiety containing rapamycin analog is in treating renal carcinoma, lung cancer, colon cancer, and breast cancers wherein potency of the drug, its half-life, tissue distribution properties, and its pharmacokinetic properties including bioavailability through oral and intravenous routes are essential to the clinical outcomes.